Schwartz, Brian
Arqule (United States)
2 papers on CoChatORCID 0000-0003-2632-6351
Most cited papers
- Verified
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Adjei, A. A., Schwartz, B., & Garmey, E. (2011) · The Oncologist
Lung Cancer Treatments and MutationsCancer Mechanisms and Therapy
Cited by 73
- Verified
A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
Eng, C., Bessudo, A., Hart, L. L., Severtsev, A., Gladkov, O., Müller, L., Kopp, M. V., Vladimirov, V., Langdon, R., Kotiv, B., et al. (2016) · International Journal of Cancer
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 72
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free